Constellation Energy and Vistra stock surge after PJM capacity auction results
Metsera , Inc. (NASDAQ:MTSR), a $2.89 billion biotech company currently trading near its 52-week high of $32.81, announced positive results from its Phase 1 clinical trial of MET-233i, a subcutaneously injectable ultra-long acting amylin analog for treating obesity and overweight. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet. The trial, which included single ascending dose (SAD) and multiple ascending dose (MAD) portions, assessed safety, tolerability, and pharmacokinetics (PK) of MET-233i.
The SAD portion enrolled 40 participants across five cohorts, with doses ranging from 0.15 mg to 2.4 mg. Results indicated dose-dependent weight loss, with the highest dose achieving a mean placebo-subtracted weight loss of 5.3% by day 8. MET-233i was generally well-tolerated, with gastrointestinal-related treatment-emergent adverse events (TEAEs) like nausea and vomiting being the most common. The market appears optimistic about these results, with analysts setting price targets between $38 and $56.
In the MAD portion, 40 participants received five weekly doses of MET-233i or placebo. The 1.2 mg dose cohort exhibited an 8.4% mean placebo-subtracted weight loss by day 36. TEAEs were mild and primarily gastrointestinal, occurring mainly in the first week. Three participants discontinued the trial, none due to TEAEs.
PK analysis revealed dose-proportional pharmacokinetics with an observed half-life of approximately 19 days. The company is advancing MET-233i as a monotherapy and in combination with MET-097i, with further trials underway. Topline data from these trials are anticipated later in 2025 or early 2026.
The information is based on a press release statement filed with the SEC.
In other recent news, Metsera, Inc. announced positive results from its Phase 1 clinical trial for MET-233i, an amylin analog aimed at obesity treatment. The trial, which involved 80 participants, demonstrated up to 8.4% mean placebo-subtracted weight loss and highlighted the potential for once-monthly dosing. Additionally, Metsera has been actively enhancing its leadership team, appointing Jon P. Stonehouse to its Board of Directors and Matthew Lang as Chief Legal Officer. In a separate development, the company approved full 2024 annual cash bonuses for its executive officers, reflecting its performance for the year ended December 31, 2024. The bonuses awarded included $241,644 for CEO Christopher Whitten Bernard and $59,836 for Executive Chairman Clive A. Meanwell. Cantor Fitzgerald maintained an Overweight rating on Metsera shares, emphasizing the company’s competitive edge and promising catalyst path. The analysts highlighted Metsera’s differentiated pipeline, designed to address various segments of the obesity market. These developments underscore Metsera’s ongoing commitment to advancing its clinical programs and strengthening its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.